MedTrace Logo

Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients

NCT03150134 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2017-05-12

No results posted yet for this study

Summary

Early reduction of immunosuppressive agents after HLA matched donor transplantation can improve the survival of advanced stage acute myeloid leukemia.

single-center, open clinical study

Conditions

Interventions

DRUG

Cyclosporine

Patients with advanced AML received early tapering of immunosuppressive drugs(Cyclosporine)

DRUG

routine reduction of immunosuppressive drugs(cyclosporine)

patients with AML in CR were given the routine reduction of immunosuppressive drugs(cyclosporine)

Sponsors & Collaborators

  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • xinpeng wang, doctor · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-01
Primary Completion
2020-01-01
Completion
2021-01-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03150134 on ClinicalTrials.gov